Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Conditions
Brief summary
This clinical trial develops and test a yoga intervention in improving cancer-related stress in cancer survivors. The online hatha yoga intervention of breathing and movement incorporates both restorative poses, breathing techniques, guided meditation and may reduce stress levels and improve overall quality of health in cancer survivors.
Detailed description
PRIMARY OBJECTIVE: I. To develop and test the feasibility of a standardized 12-week online hatha yoga intervention (n=30) of breathing and movement incorporating both restorative poses, breathing techniques, guided meditation. SECONDARY OBJECTIVES: I. To evaluate the yoga intervention in relation to self-reported levels of stress and quality of life in cancer survivors (n=30). II. Feasibility of collecting blood and saliva at baseline and post-intervention for stress biomarkers, including cortisol and norepinephrine. EXPLORATORY OBJECTIVE: I. To determine how behavior change, quality of life (QoL), and biomarkers of adrenergic stress, inflammation, and immunosuppression are affected by a 12-week online yoga program completed by cancer survivors. OUTLINE: Patients receive online yoga intervention once a week (QW) for 12 weeks. After completion of study, patients are followed up at 3 months.
Interventions
OTHERQuality-of-Life Assessment
Ancillary studies
OTHERSurvey Administration
Ancillary studies
OTHERYoga
Receive yoga intervention
Sponsors
Roswell Park Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>= 18 years of age * Have been diagnosed with a cancer and have finished treatment * Have been cleared for physical activity by a physician or nurse practitioner (physician or nurse practitioner name and date clearance received) * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion criteria
* Unwilling or unable to complete the assessment in English * Are pregnant or nursing * Are unwilling or unable to follow protocol requirements * Have skeletal instabilities and/or cardio-pulmonary comorbidities * Have any condition which in the investigator's opinion deems the subject an unsuitable candidate to participate in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of subjects who participate or show high adherence to the intervention | Up to 12 weeks | Will be presented as observed proportion and 95% Clopper-Pearson confidence intervals (CIs). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of the intervention in stress-reduction | Up to 3 months post-intervention | Serum cortisol and norepinephrine levels will be measured by blood collection |
| Efficacy of the intervention in stress reduction | Up to 3 months post intervention | salivary cortisol will be measured by saliva collection |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in Quality of life | Up to 3 months post-intervention | Quality of life collected by the EORTC Quality of Life Questionnaire |
| Change in Cognitive function | Up to 12 weeks | Cognitive function will be assessed by standard questionnaires |
Countries
United States
Outcome results
None listed